Skip to content

Humanigen in manufacturing deal with Thermo Fisher on lenzilumab

September 23, 2020

Humanigen (NASDAQ:HGEN) will collaborate with Thermo Fisher Scientific (NYSE:TMO) to expand the manufacturing capacity for lenzilumab, for use in COVID-19, to support a potential Emergency Use Authorization (EUA) application.

“Manufacturing preparation, precision and expertise are critical as we execute on an aggressive strategy, pending a potential EUA from the FDA, to deliver a COVID-19 therapeutic this winter that has the potential to reduce the risk of ventilation or death and send patients home from the hospital earlier,” said Cameron Durrant, MD, MBA, CEO.

Thermo Fisher will begin the technical transfer of the lenzilumab bulk drug substance process and commercial scale production could begin before year-end.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: